Segui
Thomas Schön
Thomas Schön
Professor in Infectious Diseases, Linköpings universitet. infektionsläkare och mikrobiolog
Email verificata su ltkalmar.se
Titolo
Citata da
Citata da
Anno
The global prevalence of latent tuberculosis: a systematic review and meta-analysis
A Cohen, VD Mathiasen, T Schön, C Wejse
European Respiratory Journal 54 (3), 2019
4572019
Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis
World Health Organization
World Health Organization, 2018
3692018
Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis
D Elias, H Akuffo, A Pawlowski, M Haile, T Schön, S Britton
Vaccine 23 (11), 1326-1334, 2005
2352005
Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives
T Schön, P Miotto, CU Köser, M Viveiros, E Böttger, E Cambau
Clinical Microbiology and Infection 23 (3), 154-160, 2017
2172017
Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis
K Ängeby, P Juréen, G Kahlmeter, SE Hoffner, T Schön
Bulletin of the World Health Organization 90, 693-698, 2012
1462012
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis
T Schön, P Juréen, CG Giske, E Chryssanthou, E Sturegård, J Werngren, ...
Journal of antimicrobial chemotherapy 64 (4), 786-793, 2009
1422009
What is resistance? Impact of phenotypic versus molecular drug resistance testing on therapy for multi-and extensively drug-resistant tuberculosis
J Heyckendorf, S Andres, CU Köser, ID Olaru, T Schön, E Sturegård, ...
Antimicrobial agents and chemotherapy 62 (2), 10.1128/aac. 01550-17, 2018
1252018
Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine)
WH Organization
World Health Organization, 2021
1032021
Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid …
TT Balcha, E Sturegård, N Winqvist, S Skogmar, A Reepalu, ZH Jemal, ...
PloS one 9 (1), e85478, 2014
1022014
Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis
T Schön, D Elias, F Moges, E Melese, T Tessema, O Stendahl, S Britton, ...
European Respiratory Journal 21 (3), 483-488, 2003
952003
Expression of inducible nitric oxide synthase and nitrotyrosineduring the evolution of experimental pulmonary tuberculosis
R Hernandez-Pando, T Schön, EH Orozco, J Serafin, I Estrada-Garcia
Experimental and Toxicologic Pathology 53 (4), 257-265, 2001
892001
Management of patients with multidrug-resistant tuberculosis
C Lange, RE Aarnoutse, JWC Alffenaar, G Bothamley, F Brinkmann, ...
The international journal of tuberculosis and lung disease 23 (6), 645-662, 2019
832019
The impact of asymptomatic helminth co-infection in patients with newly diagnosed tuberculosis in north-west Ethiopia
E Abate, M Belayneh, A Gelaw, J Idh, A Getachew, S Alemu, E Diro, ...
Public Library of Science 7 (8), e42901, 2012
832012
Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene …
J Werngren, E Sturegård, P Juréen, K Ängeby, S Hoffner, T Schön
Antimicrobial Agents and Chemotherapy 56 (3), 1253-1257, 2012
822012
Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates–the EUCAST broth microdilution reference method for MIC determination
T Schön, J Werngren, D Machado, E Borroni, M Wijkander, G Lina, ...
Clinical Microbiology and Infection 26 (11), 1488-1492, 2020
812020
Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex
M Merker, TA Kohl, I Barilar, S Andres, PW Fowler, E Chryssanthou, ...
Genome Medicine 12, 1-8, 2020
782020
Local production of nitric oxide in patients with tuberculosis
T Schön, G Elmberger, Y Negesse, R Hernandez Pando, T Sundqvist, ...
The International Journal of Tuberculosis and Lung Disease 8 (9), 1134-1137, 2004
772004
Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review
VN Dahl, M Mølhave, A Fløe, J van Ingen, T Schön, T Lillebaek, ...
International Journal of Infectious Diseases 125, 120-131, 2022
752022
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available …
KA Ängeby, P Jureen, CG Giske, E Chryssanthou, E Sturegård, ...
Journal of antimicrobial chemotherapy 65 (5), 946-952, 2010
702010
Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis
T Schön, P Juréen, E Chryssanthou, CG Giske, E Sturegård, G Kahlmeter, ...
The International Journal of Tuberculosis and Lung Disease 15 (4), 502-509, 2011
692011
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20